Press Releases Year None2021202020192018 Oct 05, 2021 Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference Sep 07, 2021 Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference Aug 13, 2021 Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update Jul 14, 2021 Akero Therapeutics Appoints Judy Chou, Ph.D., to its Board of Directors Jul 08, 2021 Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of Treatment Jun 25, 2021 Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)- Jun 21, 2021 Akero Therapeutics Presents Analyses at the 2021 International Liver Congress Showing Normalization of Liver Fat Substantially Reduced Markers of Liver Injury and Fibrosis, and Greatly Increased Probability of Resolving NASH Jun 01, 2021 Akero Therapeutics to Present Efruxifermin (EFX) Results Showing Histologic Improvement in EFX-Treated F4 Cirrhotic Patients as a Late-Breaker Oral Presentation at the 2021 International Liver Congress May 28, 2021 Akero Therapeutics to Present at the Jefferies Virtual Healthcare Conference May 13, 2021 Akero Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 18
Year None2021202020192018 Oct 05, 2021 Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference Sep 07, 2021 Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference Aug 13, 2021 Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update Jul 14, 2021 Akero Therapeutics Appoints Judy Chou, Ph.D., to its Board of Directors Jul 08, 2021 Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of Treatment Jun 25, 2021 Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)- Jun 21, 2021 Akero Therapeutics Presents Analyses at the 2021 International Liver Congress Showing Normalization of Liver Fat Substantially Reduced Markers of Liver Injury and Fibrosis, and Greatly Increased Probability of Resolving NASH Jun 01, 2021 Akero Therapeutics to Present Efruxifermin (EFX) Results Showing Histologic Improvement in EFX-Treated F4 Cirrhotic Patients as a Late-Breaker Oral Presentation at the 2021 International Liver Congress May 28, 2021 Akero Therapeutics to Present at the Jefferies Virtual Healthcare Conference May 13, 2021 Akero Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 18
Oct 05, 2021 Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference
Sep 07, 2021 Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference
Aug 13, 2021 Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
Jul 08, 2021 Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of Treatment
Jun 25, 2021 Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-
Jun 21, 2021 Akero Therapeutics Presents Analyses at the 2021 International Liver Congress Showing Normalization of Liver Fat Substantially Reduced Markers of Liver Injury and Fibrosis, and Greatly Increased Probability of Resolving NASH
Jun 01, 2021 Akero Therapeutics to Present Efruxifermin (EFX) Results Showing Histologic Improvement in EFX-Treated F4 Cirrhotic Patients as a Late-Breaker Oral Presentation at the 2021 International Liver Congress
May 13, 2021 Akero Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
